SCHEMBL29314711

SCHEMBL29314711

Nc1nc2cc(-c3cc[nH]n3)ccc2c2cn(CCNC(=O)c3ncccc3Cl)nc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
KLKB1 P03952 4/20 0.34
CSNK1D P48730 2/20 0.32
CSNK1E P49674 2/20 0.32
WNT1 P04628 2/20 0.32
DYRK1A Q13627 2/20 0.32
ADORA2A P29274 2/20 0.31
ADORA1 P30542 2/20 0.31
P2RX7 Q99572 1/20 0.31
SLC40A1 Q9NP59 2/20 0.31
NAMPT P43490 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPK1 P28482 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
MAP4K4 O95819 1/20 0.31
BACE1 P56817 1/20 0.30
AR P10275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29314649 0.91 WNT1 (0.34) TLR8TLR7KLKB1WNT1DYRK1A
SCHEMBL29320672 0.89 TLR8 (0.37) TLR8TLR7KLKB1WNT1DYRK1A
SCHEMBL29320279 0.88 KDM4E (0.38) TLR8TLR7KDM4EMEN1KMT2A
SCHEMBL29314663 0.85 KDR (0.34) TLR8TLR7KLKB1NAMPTMEN1
SCHEMBL29320239 0.85 TLR7 (0.41) TLR8TLR7NAMPTKDM4EMEN1
SCHEMBL29314679 0.85 P2RX7 (0.35) TLR8TLR7P2RX7NAMPTMAP4K4
SCHEMBL29314683 0.85 ADORA3 (0.35) TLR8TLR7CSNK1DCSNK1EP2RX7
SCHEMBL29314678 0.85 MAOB (0.38) TLR8TLR7P2RX7NAMPT
SCHEMBL29320594 0.85 TLR8 (0.35) TLR8TLR7KLKB1ADORA2AADORA1
SCHEMBL29320251 0.84 NAMPT (0.36) TLR8TLR7NAMPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037344-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2024-07-16 US disclosed
US-12037344-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2024-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037344-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD TLR8 210/4885TLR7 236/4885KLKB1 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.